18 min listen
Cancer drug trials used for regulatory approval are at risk of bias
FromThe BMJ Podcast
ratings:
Length:
27 minutes
Released:
Sep 19, 2019
Format:
Podcast episode
Description
Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, in a new study.
Huseyin Naci,assistant professor of health policy a the London School of Economics joins us to talk about why potential bias may mean potential exaggeration of treatment effects, and could be costing our health systems a great deal of money.
Read the full research:
https://www.bmj.com/content/366/bmj.l5221
Listen on apple podcasts:
https://podcasts.apple.com/gb/podcast/the-bmj-podcast/id283916558?mt=2&app=podcast
Huseyin Naci,assistant professor of health policy a the London School of Economics joins us to talk about why potential bias may mean potential exaggeration of treatment effects, and could be costing our health systems a great deal of money.
Read the full research:
https://www.bmj.com/content/366/bmj.l5221
Listen on apple podcasts:
https://podcasts.apple.com/gb/podcast/the-bmj-podcast/id283916558?mt=2&app=podcast
Released:
Sep 19, 2019
Format:
Podcast episode
Titles in the series (100)
NSAIDs update: Recent research shows that some non-steroidal anti-inflammatory drugs increase cardiovascular risk in some patients. Given their widespread use, and breadth of indications for prescription, should clinicians be more circumspect about their practice?I... by The BMJ Podcast